We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Single Tube PCR Identifies Aneuploidies in Embryos

By LabMedica International staff writers
Posted on 25 Jun 2012
A novel test is being developed for genetic abnormalities during pregnancy.

A single tube multiplex polymerase chain reaction (PCR) starting from fetal DNA isolated from the mother’s blood, allows the identification of copy number variations (or aneuploidies) of chromosomes 21, 18, 13, X and Y. More...
Such variations cause genetic diseases like Down’s syndrome, Edward’s syndrome, Patau syndrome, triple X syndrome, and Klinefelter’s syndrome.

The test needs only a blood sample, in contrast to the invasive screening methods in use today. It will be based on Multiplicom’s (Niel, Belgium) proprietary MASTR (Multiplex Amplification of Specific Targets for Resequencing) workflow.

The noninvasive aneuploidy testing (NIAT) is a novel approach that aims to replace the 250,000 invasive procedures such as amniocentesis and chorionic villus sampling performed annually in Europe. These procedures are time consuming and carry a significant risk of complications during pregnancy. NIAT is not only rapid and safe but is designed to have predictive power superior to that of conventional prenatal testing methods.

Multiplicom, a molecular diagnostics company specializing in the design, development, production, and commercialization of innovative molecular genetic tests based on massively parallel sequencing, has been awarded a USD 260,000 grant from the Flemish agency for Innovation by Science and Technology (IWT).

The grant is intended to support the development of a novel test for genetic abnormalities during pregnancy that needs only a blood sample, in contrast to the invasive screening methods in use today. The test will be based on Multiplicom’s proprietary MASTR (Multiplex Amplification of Specific Targets for Resequencing) workflow.

Dr. Dirk Pollet, CEO of Multiplicom, said: “This grant is a strong endorsement of our MASTR technology. It will allow Multiplicom to develop a new assay that will help physicians and patients enhance prenatal medical care while cutting costs. In the future, we see this test entirely replacing current invasive techniques.”

Subsequent validation studies will be conducted in close collaboration with hospitals throughout Europe. Multiplicom aims to make the test available to all accredited genetics labs as part of its drive to make personalized healthcare available to all.

Related Links:

Multiplicom




New
Gold Member
Latex Test
SLE-Latex Test
Serological Pipet Controller
PIPETBOY GENIUS
New
Chlamydia Trachomatis Test
Aptima Chlamydia Trachomatis Assay
New
DNA/RNA Extraction/Purification Kit
Nucleic Acid Extraction or Purification Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
Image: Pancreatic cancer diagnosis (Photo courtesy of World Journal of Gastroenterology)

AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis

Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. Often referred to as the "king" of all cancers,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.